29 Vesicular stomatitis virus Indiana strain G protein (VSVind.G) is the most commonly 30 used envelope glycoprotein to pseudotype lentiviral vectors (LV) for experimental and 31 clinical applications. Recently, G proteins derived from other vesiculoviruses (VesG), 32 for example Cocal virus, have been proposed as alternative LV envelopes with 33 possible advantages compared to VSVind.G. Well-characterised antibodies that 34 recognise VesG will be useful for vesiculovirus research, development of G protein-35 containing advanced therapy medicinal products (ATMPs), and deployment of 36 VSVind-based vaccine vectors. Here we show that one commercially available 37 monoclonal antibody, 8G5F11, binds to and neutralises G proteins from three strains 38 of VSV as well as Cocal, and Maraba viruses, whereas the other commercially 39 available monoclonal anti-VSVind.G antibody, IE9F9, binds to and neutralises only 40 VSVind.G. Using a combination of G protein chimeras and site-directed mutations, 41 we mapped the binding epitopes of IE9F9 and 8G5F11 on VSVind.G. IE9F9 binds 42 close to the receptor binding site and competes with soluble low-density lipoprotein 43
INTRODUCTION
for 8G5F11 and IE9F9 binding to VSVind.G were 2.76nM and 14.7nM respectively. 125 To further analyse the VesG-8G5F11 interaction we immobilised the mAb and 126 investigated VesG pseudotyped lentiviral vector (LV) binding. Since pseudotyped LV 127 particles contain many trimeric G protein spikes (33), the analysis of the interaction 128 between VesG binding to immobilised 8G5F11 reflects avidity. Dose-response 129 binding of VSVind.G resulted in a strong response implying high avidity.
130
(Supplementary Figure S1 ). When identical doses of VesG-LV at 1x10 8 TU/ml were 131 injected on immobilized 8G5F11, similar patterns of binding were observed to that of 132 quantitative flow cytometry, in the order of strength of VSVind > MARAV > VSVala > 133 Cocal > VSVnj ( Figure 2E ). Unrelated RDpro envelope pseudotyped LVs were utilised 134 as negative control to deduce unspecific interaction of enveloped particles with 135 immobilised mAb. PIRYV.G-LV demonstrated a similar response to that of indicative of the lack of binding between the G protein and 8G5F11.
137
Determining the cross-neutralisation abilities of anti-VSVind.G antibodies 138 These three antibodies were evaluated for their ability to neutralise VSVind.G and 139 VesG pseudotyped LVs (Figure 3 ). 8G5F11 demonstrated varying strengths of 140 neutralisation against VesG pseudotyped LVs, IC50 values ranging from 11.5ng/ml to 141 86.9µg/ml ( Figure 3A ). There was however limited correlation between G proteins' 142 binding strength and sensitivity of LV, e.g. VSVnj.G-LV was more sensitive than 143 COCV.G-LV ( Figure 3A ) while COCV.G binding was stronger (Figure 1 and 2). IE9F9 144 neutralised only VSVind.G-LV at 137ng/ml IC50, about 12-fold weaker than 8G5F11 145 ( Figure 3B ). In the case of VSV-Poly, we only observed cross neutralisation at high 146 serum concentrations ( Figure 3C ). Furthermore, although VSV-Poly bound to 147 PIRYV.G, it did not neutralise PIRYV.G-LVs.
148
Mapping the epitopes of anti-VSVind.G mAbs and identification of key amino 149 acid residues that dictate antibody binding and neutralisation 150 To map where the neutralising antibodies might bind to on the G protein surface a 151 series of chimeric G proteins between VSVind.G and COCV.G were constructed. The 152 initial binding and neutralisation studies performed with these chimeras enabled us to 153 narrow down the epitopes of these mAbs to lie between amino acid (aa) residues 137-154 369 1 on VSVind.G (Supplementary Figure S2 ). Furthermore, looking at previously 155 published data on 8G5F11 and IE9F9's epitopes obtained through mutant virus 156 escape assays (1, (13) (14) (15) we concentrated on two distinct regions on VSVind.G and 157 synthesized 22 different mutant G proteins to study the epitopes (Figure 4) weren't any substantial protein display issues (Supplementary Figure S3 ).
165
We first investigated antibody binding to these G proteins via flow cytometry. Relative 166 expression levels of the mutants were determined by extracellular VSV-Poly and 167 intracellular P5D4 stains. For both sets the relative difference between expression 168 levels of mutant and wt proteins was in most cases less than two-fold ( Figure 5A-B ).
169
In the case of 8G5F11, binding to VSVind.G mutants was reduced by approximately 170 100-fold while the changes on COCV.G enabled these mutants to bind to 8G5F11 at 171 similar levels to that of wt VSVind.G ( Figure 5C ). This change in binding could also 172 be observed on a western blot. While none of the VSVind.G mutants could be 173 visualized, 8G5F11 could bind to COCV.G chimera C8.3 (data not shown). It can be 174 inferred from these results that aa 257-259 (DKD) are the main residues that dictate 175 8G5F11 binding to G proteins.
176
On the other hand, for IE9F9 no statistically significant changes in antibody binding 177 were observed for VSVind.G mutants (data not shown) except for chimeras V1.2 and 178 V1.4 ( Figure 5D ). However, there was a substantial gain of binding effect for COCV.G 179 mutants. While IE9F9 doesn't bind to wt COCV.G, mutations of amino acid residues 180 LSR and AA ( Figure 4 ) alone led to significant increase in the fluorescence signal, thus 181 antibody binding, C1.4 with both LSR and AA had a comparable MFI level to that of 182 wt VSVind.G.
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Neutralisation profile of both VSVind.G and COCV.G mutants was also examined 184 ( Figure 5E -H). While LVs pseudotyped with VSVind.G mutants were not neutralised 185 ( Figure 5E ), varying degrees of sensitivity were observed for COCV.G mutants with 186 the strongest binder being the most sensitive ( Figure 5F ). On the other hand, this was 187 not the case for IE9F9 mutants. While dose-dependent neutralisation of V1.2-LV was 188 observed, VSVind.G mutant V1.4-LV was resistant to IE9F9 neutralisation ( Figure   189 5G). Furthermore, no effect was observed on COCV.G mutant LV infection even 190 though all bound to the mAb, some at similar levels to wt VSVind.G ( Figure 5H ). The
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data shows that while 8G5F11 employs a neutralisation mechanism that is universally 8G5F11 and IE9F9 with LDLR via SPR as a potential neutralisation mechanism for 201 the mAbs ( Figure 6 ). Gth immobilised on the chip surface was saturated with repeated 202 injections of 8G5F11 and IE9F9. This was followed by an injection of recombinant 203 soluble human LDLR (sLDLR) and its binding to Gth was examined. While sLDLR 204 was able to bind to Gth following 8G5F11 saturation as well as Gth without antibody 205 exposure (buffer control), this interaction was almost completely abrogated by IE9F9.
206
These data suggest that IE9F9, but not 8G5F11, neutralises VSVind.G-LV by blocking 207 the G protein-receptor interaction either through steric hindrance or direct competition. utilised are the G proteins of the other vesiculovirus family members (10-12).
217
However, one drawback of using these new G proteins is that there are no reagents 218 commercially available to identify or characterise them.
219
In this report, we have demonstrated that 8G5F11 monoclonal antibody can, unlike 220
VSVind.G specific IE9F9, cross-react with a variety of the VesG and cross-neutralise 221 VesG-LV. Furthermore, we characterised a goat anti-VSVind.G polyclonal antibody 222 which also can bind and neutralise a wide range of vesiculovirus G proteins.
223
The cross-reactive monoclonal 8G5F11 demonstrated interesting characteristics. Its 224 high cross-reactivity even towards more distant relatives of VSVind.G such as
225
VSVnj.G suggested that it might be recognising a well-conserved epitope. However,
226
the results of the binding saturation assay didn't correlate with phylogenetic relativity.
227
It revealed that its affinity towards COCV.G, one of the closest relatives of VSVind.G,
228
was one of the weakest amongst the VesG investigated with almost a 250-fold 229 difference compared to VSVind.G ( Figure 2B ).
230
This discrepancy can be explained through fine mapping of the 8G5F11 epitope. We 231 identified the amino acids 257-259, DKD, as the key residues on VSVind.G for 8G5F11 232 binding. On VSVind.G the two negatively charged aspartic acid residues flank the 233 positively charged lysine possibly contributing towards the structure of the α-helix form 234 through salt-bridges (7, 16, 17) . When either of the aspartic acid residues is mutated 235 to a neutral residue a significant reduction in binding is observed. When this is 236 compared to the corresponding three residues on other VesG, the antibody binding is 237 dependent on the overall charge of these three residues rather than the ones 238 surrounding them. In MARAV.G, these residues are identical to VSVind.G, explaining 239 why the antibody has similar strength of binding to these two G proteins 240 (Supplementary Figure S4 ). On the other hand, VSVala.G binds 8G5F11 with high 241 affinity although these residues are not fully conserved, as in VSVala.G the second 242 aspartic acid residue is replaced with a glutamic acid. But it is possible that the 243 conservation of the second negative charge and the structural similarities between 244 these two residues enable a robust G protein-antibody interaction. Lastly, VEQ 245 corresponding aa residues in PIRYV.G, VEQ, have electrostatically and structurally 246 different characteristics to that of lysine and aspartic acid leading to the lack of 247 interaction between the mAb and G protein. 248 We showed that IE9F9 recognises a β-sheet rich domain of the G protein (7, 17 VSVind.G. The lack of cross-reactivity and cross-neutralisation ( Figure 1 and 3) 281 displayed by the mAb towards VesG as well as its failure to neutralise COCV.G 282 mutants when its epitope is inserted into the G protein ( Figure 5) 
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